SINO BIOPHARMACEUTICAL
Sino Biopharmaceutical engages in pharmaceutical products which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumours, liver diseases, cardio-cerebral diseases, analgesia, respiratory system diseases and orthopedicdiseases.
SINO BIOPHARMACEUTICAL
Industry:
Biotechnology Health Care Health Diagnostics Hospital Medical Pharmaceutical
Founded:
1997-02-02
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Nginx Euro Google Apps For Business Pound Sterling Japanese Yen Java EE Network Solutions DNS Unsplash
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Fatigue Science Institute
Fatigue Science is a research, development and sales of medical technology and medical supplies for various diseases, and treatment.
Kanzawa Medical Research Foundation
Kanzawa Medical Research Foundation promotes the development of healthcare and medical science by encouraging studies.
Samjin Pharmaceutical
Samjin Pharmaceutical is a company that pioneeres a healthy life for human beings with a creative mind and advances for a prosperous future.
Current Employees Featured
Hsin Tse Executive Director and VP @ Sino Biopharmaceutical
Executive Director and VP
Yi Li President & CEO @ Sino Biopharmaceutical
President & CEO
Ping Tse Founder & Sr. Vice Chairman @ Sino Biopharmaceutical
Founder & Sr. Vice Chairman
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-03-23 | Softhale | Softhale acquired by Sino Biopharmaceutical | 110 M USD |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-06-02 | Generon (Shanghai) Corporation | Sino Biopharmaceutical investment in Venture Round - Generon (Shanghai) Corporation | 70 M USD |
| 2021-12-12 | Medlinker | Sino Biopharmaceutical investment in Series E - Medlinker | 514 M USD |
| 2021-11-18 | Treadwell Therapeutics | Sino Biopharmaceutical investment in Series B - Treadwell Therapeutics | 91 M USD |
| 2021-08-11 | XtalPi | Sino Biopharmaceutical investment in Series D - XtalPi | 400 M USD |
| 2020-12-06 | Sinovac Life Sciences | Sino Biopharmaceutical investment in Corporate Round - Sinovac Life Sciences | 500 M USD |
| 2019-11-04 | Akeso Biopharma | Sino Biopharmaceutical investment in Series D - Akeso Biopharma | 150 M USD |
| 2015-08-05 | LifeBond | Sino Biopharmaceutical investment in Series D - LifeBond | 27 M USD |
More informations about "Sino Biopharmaceutical"
Sino Biopharmaceutical Limited - Wikipedia
Sino Biopharmaceutical Limited (SEHK: 1177|Hang Seng Index component) (simplified Chinese: 中国生物制药有限公司; traditional Chinese: 中國生物製藥有限公司), shortly Sino Biopharm, …See details»
Sino Biopharmaceutical | World Economic Forum
Sino Biopharmaceutical is a leading pharmaceutical conglomerate in China, specializing in biopharmaceutical and chemical medicines. Listed on the Hong Kong Stock Exchange since 2000, it became a constituent of the MSCI Global …See details»
Presentation - Sino Biopharm
© 2023 Sino Biopharmaceutical Co., Ltd. All rights reserved. Friendly link invoX Pharma Limited CTTQ Pharmaceutical Tide Pharmaceutical CP Group CTTQ Pharmaceutical ...See details»
Sino Biopharmaceutical - Crunchbase
Sino Biopharmaceutical engages in pharmaceutical products which covers an array of R&D platforms, a line-up of intelligent production and a strong sales …See details»
Sino Biopharmaceutical - businessabc
May 29, 2025 Sino Biopharmaceutical was established in 1979 in Hong Kong and was one of the earlier pharmaceutical companies in the China region. In recent years, the company has …See details»
Sino Biopharmaceutical Company Description - Stock Analysis
Feb 6, 2025 Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It …See details»
Sino Biopharmaceutical - Investments, Portfolio & Company Exits
Sino Biopharmaceutical 's most notable exits include XtalPi, Akeso Biopharma, and LifeBond. Which industries has this organization had the most exits in? Show . XtalPi XtalPi is a …See details»
Sino Biopharm
5月18日上午，中国生物制药首席执行长谢承润，作为香港港区省级政协委员联谊会副秘书长，与联谊会苏清栋主席、霍启山会长一起，参加吉林省委书记、省人大常委会主任黄强一行来访接待活动。See details»
Sino Biopharmaceutical - Pharmaceutical Companies Database
Sino Biopharmaceutical Limited and its subsidiaries are the leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the full industry chain …See details»
Sino Biopharmaceutical, One of the Largest Chinese ... - Morningstar
May 9, 2024 Sino Biopharm has a good financial position. As of December 2023, it has CNY 9.5 billion in cash on hand and CNY 12.2 billion in debt. Total debt outstanding is 19.2% of its total …See details»
Sino Biopharmaceutical | 世界经济论坛
Sino Biopharmaceutical is a leading pharmaceutical conglomerate in China, specializing in biopharmaceutical and chemical medicines. Listed on the Hong Kong Stock Exchange since …See details»
Sinopharm Group - Wikipedia
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company.The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned …See details»
Sino Biopharmaceutical Limited - Wikiwand
Sino Biopharmaceutical Limited (SEHK: 1177|Hang Seng Index component) (simplified Chinese: 中国生物制药有限公司; traditional Chinese: 中國生物製藥有限公司), shortly Sino Biopharm, …See details»
Sino Biopharmaceutical Ltd - Company Profile - GlobalData
Sino Biopharmaceutical Ltd (Sino Biopharma), a subsidiary of Charoen Pokphand Group Co Ltd, is a research-oriented pharmaceutical company that develops, manufactures, and markets …See details»
Sino Biopharmaceutical Ltd | Reuters
Jan 24, 2022 Hong Kong-listed Sino Biopharmaceutical will sell a 67% stake in unit CP Pharmaceutical (Qingdao) for 1.82 billion yuan ($253.28 million) to entities controlled by state …See details»
Corporate Governance - Sino Biopharm
About Sino Biopharm Board of Directors Senior Management R&D R&D Team Products Product List Sustainability ESG Governance ESG Management Practices ESG Reports Investors …See details»
Sino Biopharm targets 30 innovative products by 2027
Mar 21, 2025 Sino Biopharmaceutical Limited, or Sino Biopharm, expects to have approximately five innovative products approved in China each year, bringing the total of its innovative …See details»
News - Sino Biopharm
Aug 25, 2022 On the morning of August 24, Sino Biopharm (HK.01177) held its 2022 interim results conference and the first Investor Day in Beijing. The company's Chairwoman of the …See details»
Sino Biopharm (1177.HK) Announces 2024 Annual Results
Mar 21, 2025 Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in …See details»
Sino Biopharm shows stable growth in 2023 - Chinadaily.com.cn
Apr 2, 2024 Sino Biopharmaceutical Limited, or Sino Biopharm, a leading innovative research and development-driven pharmaceutical conglomerate in China, announced on Thursday in its …See details»